Lifecore Biomedical Secures Two New CDMO Agreements with U.S. Biopharma Customer

Event summary

  • Lifecore Biomedical signed two new CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer.
  • One agreement involves a commercial site transfer for a currently marketed product, transitioning manufacturing from another CDMO to Lifecore.
  • The second agreement expands services to include a new delivery system for an existing commercial product.
  • This marks the fourth commercial site transfer agreement for Lifecore in the last five months.
  • Both programs are expected to contribute to Lifecore’s 2028 commercial revenue.

The big picture

Lifecore Biomedical's latest agreements underscore its growing role as a preferred CDMO partner for biopharmaceutical companies. The focus on commercial site transfers highlights a strategic shift towards higher-probability, revenue-generating programs. This trend aligns with the broader industry movement towards outsourcing manufacturing to specialized CDMOs, particularly for complex injectable products.

What we're watching

Revenue Timing
How the 2028 revenue contribution from these programs will materialize and whether it meets expectations.
Customer Retention
Whether Lifecore can sustain its momentum in securing additional commercial site transfer agreements.
Operational Execution
The pace at which Lifecore can successfully complete technical transfer services and meet regulatory requirements for commercial manufacture.